Ucb SA 2013 AR2
The report highlights UCB's financial and sustainability performance for the fiscal year 2013. Financially, the company achieved revenues of €3.41 billion and a recurring EBITDA of €689 million, driven by the growth of its core medicines Cimzia, Vimpat, and Neupro. On the sustainability front, UCB reduced its carbon footprint by 7%, with 50.2% of its electricity consumption sourced from renewable energy. Additionally, the company established the UCB Societal Responsibility Fund in partnership with the King Baudouin Foundation to support global health initiatives, particularly for epilepsy care in developing countries.
Company: Ucb SA
Sector: Manufacturing
Country: Belgium
Year: 2013
Type: AR2
Pages: 156
Back to company
Ucb SA
Annual Report
The report highlights UCB's financial and sustainability performance for the fiscal year 2013. Financially, the company achieved revenues of €3.41 billion and a recurring EBITDA of €689 million, driven by the growth of its core medicines Cimzia, Vimpat, and Neupro. On the sustainability front, UCB reduced its carbon footprint by 7%, with 50.2% of its electricity consumption sourced from renewable energy. Additionally, the company established the UCB Societal Responsibility Fund in partnership with the King Baudouin Foundation to support global health initiatives, particularly for epilepsy care in developing countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2013 - Dec 31, 2013
Fiscal Year
2013
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees